奥斯佩米芬是一种选择性雌激素受体调节剂,增强了寡类细胞髓化,并保护神经功能免受伤害
Wei Liu1,2, Hong Ren3, Junda Wang2
1Department of Neurosurgery of Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Journal of neurochemistry
|September 17, 2025
概括
美国食品和药物管理局批准的药物奥斯佩米芬有效地促进中枢神经系统 (CNS) 中的髓修复. 这种选择性雌激素受体调节器 (SERM) 显示出治疗多发性硬化症 (MS) 等脱髓化疾病的前景.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 再生医学是一种再生医学.
背景情况:
- 骨髓蛋白再生不足是中枢神经系统 (CNS) 损伤和多发性硬化症 (MS) 等疾病的关键问题.
- 重新使用FDA批准的药物来促进寡类细胞 (OL) 分化,为髓修复和功能恢复提供了一个可行的策略.
研究的目的:
- 调查选择性雌激素受体调节器 (SERM) 的ospemifene在促进髓修复方面的潜力.
- 在中枢神经系统损伤和脱髓化的临床前模型中评估奥斯佩米芬的疗效.
主要方法:
- 在实验室和体内评估了奥斯佩米芬对寡头细胞前体细胞 (OPC) 分化的影响.
- 在接受缺氧的新生小鼠中评估了ospemifene的保护作用.
- 在实验性自身免疫脑膜炎 (EAE) 和毒素诱导的脱髓化小鼠模型中测试了奥斯佩米芬.
主要成果:
- 奥斯佩米芬显著促进了OPC分化和髓膜形成.
- 在缺氧小鼠中,奥斯佩米芬预防了髓缺乏并保持了神经功能.
- 在EAE和脱髓化模型中,奥斯佩米芬治疗改善了功能结果,并增强了髓再生.
结论:
- 奥斯佩米芬在各种临床前模型中显示出显著的促美林效应.
- 奥斯佩米芬是一种有前途的治疗候选药物,用于治疗脱髓化疾病.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
496
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
496
Neurogenesis and Regeneration of Nervous Tissue
1.5K
In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...
1.5K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
785
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
785


